ecrin-mdr-crcClinical2021IPD Sharing (as of September 2021): NoRectal NeoplasmsColo-rectal CancerRectal NeoplasmsColo-rectal CancerInterventionalhttps://newmdr.ecrin.org/Study/2392000China9CetuximabECRIN MDRRecruitingfalseThe Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC PtsThis is an open label, multicenter, randomized study in Chinese patients with RAS and BRAF wild-type mCRC. Participants were randomly assigned to cetuximab + FOLFOX (group A) and cetuximab + modified XELOX[mXELOX] (group B). All patients in groups A and B will be treated until progression of disease(PD), death, intolerable toxicity or withdrawal of informed consent, whichever occurs first.2021-09-152392000NCT05074966